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Objectives. We sought to assess the role of aspirin in a precisely 
defined cohort with coronary disease receiving current therapy. 
Background. Prior results suggest that aspirin modestly de- 
creases cardiac mortality in patients with coronary disease. 
However, these findings reflect heterogeneous study conditions 
and earlier management s rategies. 
Methods. We utilized findings from the Multicenter Study of 
Myocardial Ischemia, which enrolled 936 subjects 1to 6 months 
after an acute myocardial infarction (n = 651 [70%]) or unstable 
angina (n = 285 [30%]). The follow-up period averaged 23 
months, with treatment determined by referring physicians. 
Results. At enrollment, 751 patients (80%) took aspirin regu- 
larly, usually 250 to 325 mg/day. Before enrollment, 291 patients 
(31%) had thrombolysis, and 352 (38%) had coronary angioplasty. 
During follow-up, cardiac death occurred in 22 patients, all-cause 
mortality in 31 and cardiac death or nonfatal myocardial infarc- 
tion in 70. Each of these outcomes was significantly ess frequent 
among aspirin users. Cardiac death rate was markedly reduced: 
1.6% for aspirin users and 5.4% for nonusers (p = 0.005). These 
differences were not explained by imbalances in predictors of 
postinfarction risk or therapy other than aspirin (Cox hazard 
ratio 0.37, p = 0.023). They persisted at least 2 years after 
enrollment. The difference in mortality rate was particularly 
prominent after thrombolysis: 0.9% for aspirin users and 8.8% for 
nonusers (p = 0.004). 
Conclusions. Reduction i  cardiac deaths among aspirin users 
is substantially greater than that reported previously. Although 
derived secondarily, our findings suggest hat current practice 
leads to situations in which aspirin exerts a long-term, life- 
protecting action, particularly after thrombolysis. 
(JAm Coll Cardiol 1996;28:326-30) 
Although aspirin is considered beneficial in several forms of 
coronary artery disease, the long-term influence of aspirin on 
cardiac mortality after acute coronary events remains uncer- 
tain. Results from many trials, combined in a recta-analysis, 
suggest hat aspirin causes a modest decrease in long-term 
cardiac mortality after acute myocardial infarction, approxi- 
mating 13% to 17% (1-3). However, the diversity of these 
trials implies that the clinical context of aspirin-related benefit 
is loosely defined. In addition, contemporary management 
strategies, uch as thrombolysis or percutaneous transluminal 
coronary angioplasty, were not used during these trials. In a 
trial predating widespread use of angioplasty, administration 
of aspirin to patients with unstable angina was associated with 
a dramatic (56% to 71%) decrease incardiac mortality (4). To 
assess the role of aspirin in a precisely defined cohort with 
coronary disease receiving current modes of treatment, we 
examined therapy and patient outcome in a secondary analysis 
of the Multicenter Study of Myocardial Ischemia, an investi- 
gation designed to measure the predictive capacity of nonin- 
vasive tests for subsequent coronary events. 
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Methods  
The Multicenter Study of Myocardial Ischemia. Multi- 
center study eligibifity. A full description of study procedures 
and findings has been published previously (5). In brief, 
between 1988 and 1991, the 15 participating hospitals enrolled 
936 patients 1to 6 months (mean 2.7) after coronary care unit 
admission for acute myocardial infarction or unstable angina. 
During this time, participating hospitals admitted 8,552 pa- 
tients for acute myocardial infarction or unstable angina; 2,096 
patients met eligibility requirements at posthospital contact. 
The diagnosis of acute infarction (651 patients, or 70% of 
enrollees) required enzymatic confirmation ofclinical findings. 
The diagnosis of unstable angina (285 patients, or 30% of 
enrollees) needed typical symptoms and ischemie lectrocar- 
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diographic (ECG) changes without enzyme abnormalities. To 
be eligible for the Multicenter Study, male and female patients 
had to be ->21 years old, able to perform an exercise test, free 
of major comorbidity and have no ECG abnormalities, drug 
use (e.g., cardiac glycosides) or devices that would interfere 
with exercise test interpretation. In addition, patients were 
excluded if they had coronary bypass urgery after the index 
coronary event and before enrollment. The resultant study 
cohort had a mean (_+SD) age of 58 _+ 10 years. Between 
hospital admission for the index event and study entry, 291 
patients (31%) had thrombolytic therapy, and 352 (38%) had 
coronary angioplasty. At study enrollment, patients had a 
clinical examination that included a complete inventory of 
regular medication use. The results of this examination were 
recorded on preprinted ata forms by trained study coordina- 
tors at the time of study entry. Data forms were reviewed for 
accuracy by the examining physicians before ntry into the data 
base. 
Follow-up. Once enrolled, patients had an exercise toler- 
ance test with thallium-201 scintigraphy and an ambulatory 
ECG. They were then contacted by study coordinators every 4 
months for the ensuing 6 to 43 months (mean 23) to ascertain 
recurrent hospital admissions and other study information, 
including all current regular medication use. Appropriate data 
were abstracted from hospital records to document the nature 
of end point events. Throughout the study, treatment plans, 
including decisions regarding the use of aspirin, remained at 
the discretion of referring physicians. 
Endpoints. Study end points--death from a cardiac ause, 
nonfatal myocardial infarction, and unstable angina-- 
occurred on or before November 30, 1991. The criteria for 
diagnosing a nonfatal myocardial infarction during the 
follow-up period were the same as those applied to index 
coronary events. The diagnosis of unstable angina required a
coronary care unit admission for increasing anginal symptoms 
plus either transient ischemic-type ECG changes or an in- 
crease in antianginal therapy, or both, but without enzyme 
level increases indicative of an acute infarction (5). An external 
committee r viewed information on end point events obtained 
from medical records. 
Statistical methods. All reported p values are two-sided. 
Chi-square tests were used to compare baseline characteristics 
of patients with and those without regular aspirin use except 
for age, where a t test was utilized. 
We hypothesized that regular aspirin use at study enroll- 
ment was associated with a subsequent reduction in cardiac 
death or nonfatal infarction, whichever occurred first. Initially, 
these hypotheses were tested by chi-square methods. The 
observation of a statistically significant reduction (p = 0.005) in 
cardiac mortality among those using aspirin regularly justified 
more detailed examination of treatment subsets. Cox propor- 
tional hazards models were used to test the independence of 
regular aspirin usage from established predictors of postinfarc- 
tion mortality risk (EGRET statistical software). These models 
were constructed from a list of 12 preselected clinical covari- 
ates. A backward selection procedure was used to identify 
Table 1. Aspirin Usage at Baseline 
Aspirin Dosing No. (%) of Patients* 
Once daily 
325 mg 585 (62%) 
250 mg 93 (10%) 
160 mg 6 (1%) 
80 mg 29 (3%) 
Once every other day 
325 mg 11 (1%) 
Other dosing pattern 27 (3%) 
Total regular aspirin use 751 (80%) 
No regular aspirin use 185 (20%) 
*Percentages refer to total number of enrollees in the Multicenter Study of 
Myocardial Ischemia (936 patients). 
important predictors of time to cardiac death. A p value ->0.10 
was used to remove variables in constructing the basic clinical 
model. The contribution of regular aspirin use was then 
assessed. Similar methods were used to evaluate whether the 
aspirin effect was independent of other treatment modalities. 
The effects of regular aspirin usage on time to cardiac death 
were evaluated graphically by Kaplan-Meier curves (6); the 
log-rank statistic was used when comparing two such curves. 
Resu l ts  
Aspirin usage. Aspirin was taken regularly by 751 patients, 
representing 80% of the Multicenter Study cohort (Table 1). 
At follow-up visits 8 to 18 months after study entry, 695 (93%) 
of the 751 patients continued to take aspirin regularly. Of the 
regular aspirin users, 676 (90%) took a single 250-mg or 
325-mg dose daily; regular aspirin doses averaging <250 mg 
daily were used by relatively few. No regular aspirin was taken 
by 185 patients (20% of study enrollees). 
Baseline clinical features and treatment history. At base- 
line assessment 1 to 6 months after an index myocardial 
infarction or episode of unstable angina, regular aspirin users 
and nonusers had generally similar clinical features (Table 2). 
No significant differences were noted in age, gender, athero- 
sclerotic risk factors or type of index event. The frequency of 
thrombolytie therapy for an index infarction was also distrib- 
uted equally between aspirin users and nonusers. Treatment 
with coronary angioplasty or beta-adrenergic blocking agents, 
however, was significantly more frequent among aspirin users. 
As anticipated, 53 of the 77 patients receiving warfarin were in 
the group not using regular aspirin. 
Long-term outcome. During an average follow-up period 
of 23 months, the cardiac death rate was 70% lower among 
regular aspirin users than among nonusers (p = 0.005) (Table 
3). Kaplan-Meier analysis demonstrated a significant reduction 
in cardiac mortality for regular aspirin users that became 
evident after several months of observation and persisted at 
least 2 years after study entry (Fig. 1). Similarly reduced 
cardiac death rates were noted among those aspirin users 
entering the Multicenter Study after an index myocardial 
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Table 2. Baseline Characteristics of Patients Taking Aspirin 
Regularly and Those Not Taking Aspirin Regularly 
Regular Aspirin No Regular Aspirin 
Clinical Feature (n = 751) (n = 185) 
Mean age (yr) 58.0 59.2 
Male 77.4 70.8 
Angina in past mo 30.5 36.8 
MI before index event 18.9 21.1 
Index event 
Q wave MI 42.6 48.7 
Non-Q wave MI 27.2 20.0 
Anterolateral MI* 20.0 26.5 
Unstable angina 30.2 31.4 
Diabetes mellitus 5.1 7.6 
Smoking (current) 13.6 14.1 
Hypertension 40.8 44.3 
Pulmonary. congestiont 15.6 21.2 
Treatment history 
Thrombolysis? 31.2 31.0 
Coronary angioplasty~ 41.0 23.8§ 
Beta-blockers 53.0 43.2§ 
Calcium channel blockers 55.0 57.3 
Warfarin 3.2 28.6§ 
Diuretic drugs 9.6 15.7 
*Includes Q wave or non-Q wave myocardial infarction (MI) in anterior or 
anterolateral location, tDuring index hospital period. SDuring or after index 
hospital period. §p < 0.02 versus regular aspirin. Data presented are percent- 
ages, unless otherwise indicated. 
infarction and those entering after an index episode of unsta- 
ble angina (Table 3). The cardiac mortality difference between 
aspirin users and nonusers in the smaller subgroup entering 
the study with unstable angina was not significant, even though 
the magnitude of the difference resembled that observed in the 
larger subgroup with an index infarction. 
All-cause mortality was significantly lower in patients taking 
regular aspirin, with a reduction similar to that seen for cardiac 
mortality. Severe cardiac recurrences during follow-up, defined 
Table 3. Long-Term Outcomes for Patients Taking Aspirin 
Regularly and Those Not Taking Aspirin Regularly 
Regular No Regular 
Total Aspirin Aspirin p 
Events (n = 751) (n = 185) Value* 
Cardiac death~ 22 1.6 5,4 0.005 
Index infarction 14 1.3 (7/524) 5,5 (7/127) 0.009 
(n = 651) 
Index unstable angina 8 2.2 (5/227) 5.2 (3/58) NS 
(n - 285) 
All-cause mortality 31 2.5 6.5 0.011 
Cardiac death or nonfatal 70 6.5 11.4 0.029 
infarction 
Nonfatal infarction 53 5.3 7.0 NS 
Unstable angina 125 13.9 11.4 NS 
*Regular aspirin versus no regular aspirin. ?Data are given for the entire 
Multicenter Study cohort followed by data for subgroups based on whether the 
problem initiating study enrollment was a myocardial infarction or an episode of 
unstable angina. Data presented are percent (number) of patients in group. 
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Figure 1. Kaplan-Meier plot of cardiac mortality for patients using 
aspirin regularly (dashed line) and those not using aspirin regularly 
(solid line), with days since study enrollment (1 to 6 months after an 
index coronary event prompting hospital admission--either acute 
myocardial infarction or unstable angina) shown on the horizontal 
axis. At study entry, 751 patients were regular aspirin users (A), and 
185 were nonusers (NA). The numbers of patients contributing to 
subsequent points on the plot are depicted (A/NA) just above the 
horizontal axis. The progressive decline in these numbers with time 
reflects study enrollment and follow-up techniques, with a steady 
decrease in patients followed for increasingly prolonged intervals. The 
nine patients who died of noncardiac auses were removed from the 
analysis (censored) at the time of death. The log-rank statistic indi- 
cated a highly significant decrease in cardiac mortality among regular 
aspirin users relative to nonusers (p = 0.0028). This difference 
persisted undiminished throughout the period of follow-up, which 
averaged 23 months. 
as cardiac death or nonfatal myocardial infarction, were also 
reduced in patients taking aspirin. However, the frequency of 
nonfatal myocardial infarction, taken separately, was similar 
among aspirin users and nonusers. In addition, unstable angina 
was observed about equally often during follow-up in aspirin 
users and nonusers. 
Covariates. The role of covariates was explored using a 
Cox proportional hazards regression analysis (Table 4). Pro- 
vided with data regarding 14 clinical variables (not including 
medications), the algorithm selected age, prior myocardial 
infarction, insulin-dependent diabetes mellitus and cigarette 
smoking as potent and independent predictors of prognosis 
during follow-up. Regular aspirin use, when added to this basic 
model (Table 4 [Add A]), provided significant additional 
independent prognostic information (p = 0.023). The associ- 
ated hazard ratio (odds of cardiac death per unit time among 
aspirin users relative to nonusers) was 0.37, implying a reduc- 
tion in risk of 63%. 
The Cox regression analysis was also applied to evaluate 
whether the reduction in cardiac deaths associated with regular 
aspirin use could be attributed to a concomitantly greater use 
of beta-blockers or coronary angioplasty. When information 
regarding aspirin use, beta-blocker use and an interaction term 
were added to the basic model, the predictive power of regular 
aspirin use was retained, and the associated hazard ratio was 
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Table 4. Cox Regression Analysis of Cardiac Mortality in 
Multicenter Study of Myocardial Ischemia 
Hazard Ratio 
(95% confidence p 
interval) Value 
Basic model 
Age 1.61 (1.01-2.55) 0.04 
Prior myocardial infarction 2.41 (1.03-5.65) 0.04 
Diabetes mellitus 3.08 (0.98-10.56) 0.07 
Smoking 2.72 (0.95-7.79) 0.06 
Add: 
A. Regular aspirin use 0.37 (0.16-0.87) 0.023 
B. Regular aspirin use 0.36 (0.12-1.08) 0.069 
Beta-blocker use 0.83 (0.21-3.27) 0.791 
Interaction 1.14 (0.19-6.80) 0.883 
C. Regular aspirin use 0.41 (0.17-1.03) 0.059 
Coronary angioplasty 0.49 (0.06-4.01) 0.506 
Interaction 0.77 (0.06-10.12) 0.845 
unaltered (Table 4 [Add B]). A similar result was obtained 
when the same methods were applied to coronary angioplasty 
(Table 4 [Add C]). Thus, the Cox regression analysis indicated 
that the reduction in cardiac mortality associated with regular 
use of aspirin was not explained by an accompanying rise in 
frequency of treatment with either beta-blockers or coronary 
angioplasty. The aspirin-related influence on cardiac mortality 
was also independent ofany other clinical feature xamined in 
the Multicenter Study. 
An imbalance in warfarin use was further considered as a 
source of difference between regular aspirin users and nonus- 
ers. Warfarin might have identified patients with poor left 
ventricular function and, accordingly, a worsened prognosis. 
However, only one Multicenter Study patient aking warfarin 
experienced cardiac death; this patient was not taking regular 
aspirin. Correction for imbalances in warfarin use did not 
diminish the association of regular aspirin use with reduced 
cardiac mortality. On the contrary, when patients were 
grouped according to anticoagulant use, the contrast in cardiac 
death rates was further enhanced: 1.6% in the 804 patients 
taking either warfarin or aspirin and 6.8% in the 132 patients 
taking neither of these drugs. 
Effects of regular aspirin use after thrombolysis or coro- 
nary angioplasty. To examine the interaction of contemporary 
therapy and aspirin use, patients were grouped according to 
use of thrombolysis or coronary angioplasty between index 
admission and study baseline. They were further grouped by 
regular aspirin use or nonuse (Table 5). Patients with throm- 
bolytic therapy showed a striking 90% reduction in cardiac 
death among the 234 regular aspirin users relative to the 57 
nonusers. Regular aspirin use was also associated with reduced 
cardiac death in patients not receiving thrombolytic therapy, 
but this tendency was not statistically significant. 
Cardiac death tended to be lower in the 308 subjects using 
aspirin regularly after coronary angioplasty relative to the 44 
subjects not using aspirin regularly after angioplasty. Only 
three cardiac deaths occurred in all patients with angioplasty, 
Table 5. Cardiac Deaths in Patients Grouped by Thrombolysis or
Coronary Angioplasty 
Cardiac Deaths 
No. of Regular No Regular p 
Patients Aspirin (%) Aspirin (%) Value* 
Thrombolysist 291 0.9 (2/234) 8.8 (5/57) 0.004 
No thrombolysist 643 1.9 (10/526) 3.9 (5/127) NS 
Angioplasty 352 0.6 (2/308) 2.3 (1/44) NS 
No angioplas~ 584 2.3 (10/443) 6.4 (9/141) 0.026 
*Regular aspirin versus no regular aspirin, tThrombolytic status is unknown 
in two surviving patients. 
and the tendency toward lower cardiac mortality with regular 
aspirin use was not statistically significant. A significant differ- 
ence was observed in patients without angioplasty: The 443 
nonangioplasty patients taking regular aspirin had a 65% lower 
cardiac mortality rate than the 141 not taking regular aspirin 
(p = 0.026). These data corroborate the outcome of the Cox 
regression analysis--aspirin was associated with a substantial 
decrease in cardiac deaths even when all subjects who had 
coronary angioplasty were excluded. The large reduction in 
mortality in patients taking aspirin cannot be attributed to the 
greater likelihood of these patients undergoing angioplasty. 
Discuss ion  
Regular aspirin use and cardiac mortality. This secondary 
analysis of data from the Multicenter Study of Myocardial 
Ischemia shows that regular aspirin use after a coronary event 
is associated with a substantial long-term reduction in cardiac 
and all-cause mortality. Although aspirin users are more likely 
to take concomitant beta-blockers and to have prior coronary 
angioplasty, these imbalances do not account for the markedly 
lower mortality of aspirin users: the mortality benefit associ- 
ated with regular aspirin use is independent of these factors 
(Table 4). 
Our study findings are unique in that the aspirin-related 
mortality decrements are substantially arger than estimated 
previously and are approximately equivalent in patients pre- 
senting initially with acute myocardial infarction or unstable 
angina. In contrast o a postinfarction mortality reduction 
estimated at 13% to 17% (1-3), our measures of hazard ratio 
(Table 4) indicate an aspirin-related ecrease in postevent 
mortality of -63%. Our findings are in agreement with large 
decreases in long-term cardiac mortality noted when patients 
with unstable angina were given regular aspirin (4). Discrep- 
ancies with previously published results may be due to the 
secondary nature of the analysis and the relatively small 
number of end point events (22 cardiac deaths) available for 
the examination. However, the large magnitude and consis- 
tency of the discrepancies suggest that these may well reflect 
meaningful differences in the study cohort and the use of 
contemporary therapeutic measures. The Multicenter Study 
cohort was selected, in part, on the basis of ability to perform 
an exercise stress test. Patients' relatively preserved exercise 
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capacity was associated with a favorable overall cardiac mor- 
tality rate, 2.4% during an observation period averaging 23 
months. It is possible that less severely incapacitated patients 
have a better chance at increased longevity because of the 
antithrombotic effects of aspirin. In addition, the observation 
period for the Multicenter Study began early after the index 
event--an average of 2.7 months and, in all cases, within 6 
months. This means that aspirin was evaluated at a time when 
recurrent hrombotic events were most likely to occur. This 
was not consistently true of previous tudies included in the 
recta-analysis often used to estimate aspirin's effects on postin- 
farction mortality (2,3). The two trials in the meta-analysis 
initiating therapy within 2 months (the second Medical Re- 
search Council trial [Cardiff-II] and the Micristin Study) 
tended to show a greater aspirin-related benefit han a large 
trial (Aspirin Myocardial Infarction Study [AMIS]) starting at 
2 to 60 months after infarction (2). 
Regular aspirin use after thrombolysis or coronary angio- 
plasty. Our data suggest that current medical practice leads to 
situations in which aspirin exerts a long-term, life-protecting 
influence. In contrast o patients in earlier, randomized trials 
of aspirin, the Multicenter Study cohort often received treat- 
ment with thrombolytic agents or coronary angioplasty before 
enrollment. Patients given thrombolytic therapy at their index 
coronary event appeared to have a uniquely large reduction in 
coronary mortality with long-term regular use of aspirin. 
Thrombolytic therapy might leave residual coronary lesions 
that have a long-term proclivity to recurrent hrombosis (7). 
Aspirin treatment could provide crucially important protection 
for such lesions. Aspirin is also known to reduce late occlusive 
events after coronary angioplasty (8). Although a beneficial 
action of aspirin on cardiac mortality after angioplasty was not 
clearly demonstrable in the present analysis, such action may 
have contributed to the overall improvement in mortality 
observed in regular aspirin users. However, a significant 
aspirin-related mortality decrement was seen in patients with- 
out angioplasty. The beneficial influence of aspirin cannot be 
ascribed exclusively to an association with angioplasty, which 
may itself convey mortality benefit, or to an aspirin-mediated 
protection from reocclusion at the site of prior angioplasty. 
Although our study linked regular aspirin use to reduced 
coronary mortality, there was no indication of an aspirin- 
mediated ecrease in nonfatal myocardial infarction or unsta- 
ble angina (Table 3). Aspirin use has been found to decrease 
nonfatal infarction in several randomized trials, some of which 
did not show an associated ecline in cardiac mortality (2,3). 
However, this does not imply that our findings are incompat- 
ible with prior randomized studies. In the Multicenter Study, 
aspirin may have modified ischemic events, converting some 
potentially fatal episodes to nonfatal infarctions or unstable 
angina. This effect ends to increase the observed number of 
nonfatal infarctions. Occurrence rates for nonfatal infarction 
in patients taking regular aspirin may reflect a balance of the 
two aspirin-mediated actions. 
Therapeutic implications, Our results indicate that regular 
aspirin use after a coronary event was associated with a 
reduction in long-term mortality that was much greater than 
predicted from previously published ata. It is noteworthy that 
20% of the Multicenter Study cohort were not taking aspirin 
regularly despite widely accepted recommendations for its use 
after a coronary event. If this was because of a generally 
noncompliant attitude, lack of regular aspirin use may have 
been one of many beneficial recommendations that were not 
accepted. In part, this utilization pattern may have reflected 
physician and patient underestimation f aspirin's potential 
benefits based on earlier estimates of mortality reduction. In 
the study cohort, lack of universal aspirin use may have had a 
significant adverse impact on overall mortality. If the 132 
patients who took neither aspirin nor warfarin had actually 
taken aspirin and experienced the low mortality rate of aspirin 
users, 7 of the 9 deaths in this group would not have occurred. 
Only 15 patients would then have died in the entire study 
cohort, and the overall study mortality rate would have been 
reduced by 32%. This hypothetic outcome is unproved and is 
unlikely to be evaluated by randomized prospective trial. 
Nevertheless, it seems probable that significantly more patients 
could take aspirin regularly after a coronary event and that 
these patients would, accordingly, have fewer deaths. Our 
findings suggest that more frequent use of aspirin on a regular 
basis would have striking benefits for important patient sub- 
groups, particularly those with prior thrombolytic therapy and 
possibly those with preserved exercise capacity. More wide- 
spread use of aspirin could represent a practical, inexpensive, 
helpful step in lowering overall mortality after a coronary 
event. 
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